Signe Erickson

Signe Erickson has a diverse and extensive work history in the medical and research field. Signe currently holds the position of Chief Operating Officer at Myra Vision, starting in April 2023. Prior to this, they served as the Chief Scientific Officer at Spiral Therapeutics from April 2019 to March 2023.

Signe also has experience at Genentech, where they held multiple roles including Senior Medical Science Director from February to November 2018, and Director of Device Development and ForSight VISION4 Site Lead from March 2017 to February 2018.

Before their time at Genentech, Signe had an extensive tenure at ForSight VISION4, where they held the positions of Senior Vice President of Product Development from August 2015 to March 2017, and Vice President of Development and Clinical Application from December 2009 to August 2015.

Signe began their career at SurModics as the Director of Ophthalmology R&D from January 2005 to December 2009, followed by a role as an Assistant Professor at USC, Doheny Eye Institute from September 2001 to December 2004. Prior to that, Signe worked as a Research Fellow at Johns Hopkins, Wilmer Eye Institute from June 2000 to August 2001, and as a Scientist at AtheroGenics from January 1998 to June 2000.

Signe Erickson completed their Bachelor of Science in Mechanical Engineering at Auburn University between 1987 and 1991. Signe later pursued their Ph.D. in Bioengineering at the Georgia Institute of Technology, which they successfully earned between 1991 and 1997.